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versus 0.4%), and just fell within the pre-defined non-
inferiority margin of 4.5%. However, in patients with low risk 
factors like suggested by the ESTRO or ASTRO consensus’ 
criteria, there were not statistically different LLRs in both 
arms, and also in patients with luminal A molecular subtype 
the LLR was very low in the IORT arm, about 1%. It was also 
found that there was no significant difference in the 5-year 
overall survival rate in two arms, that is, 96.8% in the ELIOT 
arm and 96.9% in the EBRT arm. For patients with higher risk 
factors, a new strategy has been now developed, which 
include a hypofractionated WBI to be given after surgery and 
ELIOT. The TARGIT-A trial was a multicentric trial. The 
inclusion criteria were stricter than in the ELIOT trial. It 
included patients with unifocal small breast cancer with non-
lobular histology and tested the concept of risk-adapted 
single-dose IORT, which was followed by external-beam WBI 
in patients with additional unfavorable risk factors. The 
latest published results from the TARGIT-A trial, with a 
median follow-up of 2 years and 4 months, reported a LRR 
with IORT of 3.3% and with EBRT of 1.3, meeting the non-
inferiority margin of 2.5%, set at the outset. Overall, breast 
cancer mortality in the IORT arm was 2.6% versus 1.9% in the 
WBI arm. In addition, non-breast cancer deaths were found to 
be significantly reduced in the IORT arm: 1.4% versus 3.5%, 
with p = 0.0086. Toxicity and cosmesis were assessed by 
different methods in the studies, but in any case a favorable 
outcome has been shown. The comparison between the 
current standard or alternative PBI approaches for early stage 
breast cancer with data coming IORT techniques poses a 
dilemma as to when preliminary results are sufficiently 
mature to be allow practitioners and patients to consider a 
new treatment approach as safe. We know that most data 
from studies of breast conservation therapy have 
demonstrated the importance of long-term data (up to 20 
years) in determining the ultimate efficacy of a treatment. 
The level 1 randomized evidence produced by the IORT trials 
show that this technique is very convenient for the patient, 
effective and has few side effects, rather than any 
postoperative treatment or procedures. Patients have every 
right to be offered an informed choice. 
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Several clinically controlled randomized trials on accelerated 
partial breast irradiation (APBI) are currently being 
conducted and some of these have now published results. 
The trials have used different strategies, for example 
different patient selection criteria, doses and number of 
fractions, overall treatment time, treated volume and 
radiation techniques. Many trials have compared the APBI 
treatment to whole breast irradiation (WBI) 50 Gy/25 fr 
followed by a boost. External beam APBI is an attractive 
strategy, because every radiation department will be able to 
do the dose planning. The demand for technical skills is in 
principle not higher than for conventional dose planning. Few 
randomized trials have reported data, but unfortunately the 
largest one has not been promising.  
In the phase III randomized RAPID trial significantly worse 
cosmetic outcome was reported with median follow up 36 
months in 2135 patients randomized 1:1 to APBI based on 3D-
CRT with 38.5 Gy/10 fractions, 5 days, versus WBI based on 
42.5Gy/16 fr or 50Gy/25 fr +/-boost. Adverse cosmesis was 
higher in APBI-treated patients compared with WBI patients 
as assessed by trained nurses (29% vs 17%; p=0.001) and by 
patients (26% vs 18%; p=0.02). Grade 3 adverse events were 
seen in 1.4% of APBI patients, and not in WBI patients. With 
median 5 years follow up data from another phase III trial 
involving 520 patients randomized to APBI with IMRT using 30 
Gy/5 fr versus WBI using 50 Gy/25 fr + boost has been 
reported by Livi and coworkers. Significantly better results 
were seen in APBI patients regarding acute (p=0.0001), late 
(p=0.004) and cosmetic morbidity (p=0.045). Local 
recurrence was seen in 1.5% of the patients. Thus data from 
large phase III trials supporting routine use of external beam 
APBI at the present time are not available. However, it is to 
be expected that the UK IMPORT LOW Trial will be able to 
report data from >2000 patients with median 5 years follow 
up at the Early Breast Cancer Conference (EBCC) March 2016. 
In that trial the strategy is based on 40 Gy/15 fr in all 3 arms, 
where arm 1 is WBI, arm 2 is partial breast irradiation, and 
arm 3 has a gradual dose using 40 Gy/15 fr to partial volume 
and 36 Gy/15 fr to residual breast. At EBCC, data on 
morbidity will also be reported from the DBCG PBI trial, 
which has included >800 patients and randomized them to 
APBI versus WBI using 40 Gy/15 fr in both arms. Data from 
these 2 trials will be presented and discussed at ESTRO 35. If 
the results from the IMPORT LOW Trial show that PBI using 40 
Gy/15 fr is safe, and these data are supported by results from 
the DBCG PBI trial using the same treatment, then there is 
support for the statement that IMRT is the best for PBI. 
However, we are also awaiting results from the ongoing 
NSABP B-39/RTOG 0413 trial, which has accrued >4000 
patients, who were randomized to APBI versus WBI. The 
majority of patients in the APBI arm have been treated with 
3D-CRT. Many of the APBI trials were designed and initiated a 
decade ago, where the local recurrence risk was higher than 
we see today. Therefore some of these trials are 
underpowered to support the statement they are 
investigating. It is to be expected that results from several 
trials investigating external APBI will be published in the near 
future, and hopefully results from the trials will be included 
in meta-analyses to achieve enough statistical power to 
identify subgroups of patients where APBI is safe and other 
subgroups where WBI is to be preferred. 
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Partial breast irradiation (PBI) can be performed with various 
techniques including both brachytherapy (BT) and external 
beam radiotherapy (EBRT). These methods differ from each 
other regarding technical skill and dosimetric characteristics. 
Recent developments in imaging, dose calculation algorithms 
and beam delivery techniques have made all methods 
clinically feasible, but in most institutions the applied 
method mostly depends on the physician's preference and the 
technical availability.  
Among all techniques the longest experience exists with 
multicatheter interstitial BT which can provide highly 
conformal dose distribution, large dose gradient at target 
edge, but it is quite complex and requires certain manual 
skilfulness. The possible geometric miss can result in 
significant under dosage of the target.  
Technically, the intracavitary applicators are easier to be 
used and with balloon-type applicators no geometric miss can 
occur, but proper tissue conformance is not always 
guaranteed. In dosimetric point of view drawbacks of the 
Mammosite applicator are the spherical dose distribution, the 
symmetric margin and the potential high dose to skin, lungs 
and ribs. In some anatomical situation the balloon can be 
asymmetric resulting in asymmetric target coverage. The 
multichannel applicators are more flexible regarding shaping 
the dose distribution and reducing dose to critical structures 
without compromising the target volume coverage. With 
these applicators asymmetric margins can be used to a small 
degree.  
In intraoperative electronic BT using spherical applicators 
the dose distribution is also spherical and a large dose 
inhomogeneity develops due to the sharp dose fall-off of the 
low energy X-ray beam. The margin is always symmetric, but 
the geometric accuracy is always ensured.  
At intraoperative irradiation with electron beams there is 
no 3D-defined target volume, modulation possibilities to 
shape the dose distribution are very limited and conformal 
radiotherapy cannot be performed.  
Linear accelerator based EBRT techniques expose relatively 
large volumes of non-target breast to high dose mainly due to 
the extended target volume created from CTV. In three-
dimensional conformal radiotherapy (3D-CRT) dose to 
contralateral breast, lung or heart can be reduced with 
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proper selection of beam orientations. With intensity 
modulated radiotherapy (IMRT) highly conformal dose 
distribution can be achieved, but volumes irradiated by low 
doses can be larger than with 3D-CRT. Regarding the dose to 
OARs, with multicatheter BT the critical structures can be 
better spared than with 3D-CRT/IMRT except for the heart 
whose dose in BT is strongly dependent on the location of the 
PTV. With image guidance in EBRT the dose to OARs can be 
significantly reduced. At left sided lesion the dose to heart 
can be considerably decreased with deep inspiration breath-
hold technique. 
With special EBRT equipments such as Cyberknife or 
Tomotherapy which are equipped with image guidance 
smaller CTV-PTV margin can applied which reduces the dose 
to OARs while maintaining proper target coverage. Real-time 
tracking with Cyberknife can provide better target volume 
coverage and spare nearby critical organs, but the treatment 
time is too long.  
Proton beam irradiation, due to the more favourable dose 
characteristics of proton beam, can provide the less dose to 
organs at risk, but the availability of the technique is sparse.  
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During the past decade many investigations have been 
performed to investigate and minimize clinical uncertainties 
that could lead to significant deviations between the planned 
and the delivered doses in radiotherapy. Among the sources 
of uncertainties patient setup plays an important role in 
EBRT. Analogously, in brachytherapy the geometric 
uncertainties caused by movement or reconstruction 
uncertainties of the implant position in relation to the CTV 
and/or normal tissue can lead to systematic or random 
variations between prescribed and delivered dose. At the 
same time interfraction or intrafraction variations of the 
anatomy, e.g. caused by variations of position, shape and 
filling status of OARs, during the course of a treatment pose 
an additional challenge to all types of radiotherapy. 
Recent investigations of different types of uncertainties for a 
variety of treatment sites, including gynaecological, 
prostate, head and neck, or breast BT, have led to numerous 
reports on accuracy of image guided brachytherapy. These 
have triggered the development of the recommendations for 
reporting uncertainties in terms of their dosimetric impact 
(GEC-ESTRO / AAPM guidelines, Kirisits et al. 2014, Radiother 
Oncol 110). Following these guidelines for uncertainty 
analysis, individual BT workflows can be analysed in order to 
identify those components of the overall uncertainty budget 
which will have the largest impact on the total delivered 
treatment dose. Once identified, strategies for reducing 
these uncertainties can be taken into consideration, such as 
repetitive/near treatment imaging, advanced online dose 
verification tools, etc.  
In order to assess the clinical benefit of such uncertainty 
reduction measures, it is important to understand the 
interplay between different types of uncertainties and their 
combined effect on clinical outcome, in terms of TCP and 
NTCP. In the past, dose-response relationships have been 
derived from clinical data, which could not take into account 
the accuracy of the reported dose. For some treatment sites, 
e.g. for cervical cancer, uncertainty budgets and dose-
response relations have been described in the literature in 
sufficient detail that now allows us to simulate what impact 
specific clinical uncertainties would have on TCP/NTCP 
modelling. In addition to that, one can simulate how TCP or 
NTCP models would change, if systematic and random 
dosimetric uncertainties could be reduced.  
In this presentation a few such simulation examples will be 
shown to illustrate the clinical impact of uncertainties for 
source calibration, applicator reconstruction, interobserver 
variations and anatomical interfraction variations. Strategies 
for reducing clinical uncertainties will be discussed.  
Finally, we will come one step closer to answering the 
questions whether reducing our clinical uncertainties is 
possible and meaningful, and if so, which strategies would 
have the largest clinical impact. In the future dose 
prescription may be affected by technological improvements 
that lead to a reduction of dosimetric uncertainties and a 
subsequent widening of the therapeutic window. These 
developments would benefit from a common effort in the BT 
community to investigate dose-response relationships for 
various treatment sites, and to simultaneously report 
uncertainty budgets for the underlying workflows applied for 
image guided brachytherapy, in our current clinical practice.  
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The probability of local tumor control is limited by the 
amount of dose deliverable to the tumor, which is limited by 
the amount of radiation induced toxicity. There is a large, 
and currently unpredictable, interpatient variation in the 
amount of observed toxicity. Since the expected patient 
specific toxicity is not known, the prescribed dose is 
restricted such that, within the patient population, the 
number of patients with major or even fatale toxicity is 
limited. Due to the interpatient variation in toxicity the 
population based dose limits lead to undertreatment of 
patients with low normal tissue irradiation sensitivity. This 
issue could be addressed if, on a patient specific level, it 
would be possible to classify the patients according to 
expected toxicity prior to or early during the treatment 
course – which calls for predictive models of toxicity.  
Many clinical factors such as performance status, patient 
age, and other co-morbidity are associated with observed 
toxicity, and models based on such factors are today 
available (e.g. http://www.predictcancer.org/). The models 
can be a useful tool to optimize the treatment on the 
population level, but in order to be used on a patient specific 
level, input of more patient specific information is needed. 
During planning and delivery of radiotherapy a large number 
of patient images are acquired. The information content in 
the images is often reduced to a few figures (e.g. volume of 
tumor or measurement of patient positioning). The different 
types of images (CT/SPECT/PET/MR/CBCT) are available for 
free, and it is tempting to believe that these images could 
provide more patient specific information, if extracted in a 
proper way. Also as part of the response evaluation it is likely 
that imaging could be used to quantify the degree of toxicity. 
At the end of the day, the overall toxicity level can only be 
assessed by the patient, who should cope with the toxicity on 
a daily basis. However, in terms of biological tissue response 
to the radiation, patient (or oncologist) reported toxicity is 
likely to underestimate the “true” amount of toxicity since 
the toxicity effects might be overshadowed by treatment 
related gains e.g. re-ventilation of obstructed airways due to 
tumor regression in lung cancer patients, or because the 
toxicity is assumed to be related to co-morbidity. 
Disentanglement of such effects is desirable during creation 
of predictive models of toxicity; which might be feasible by 
evaluation of follow-up images.  
The most used imaging-based feature to predict toxicity is 
obviously measurement of dose to individual risk organs (e.g. 
dose to heart or lung). These values are routinely used 
clinically and typical not regarded as image-based features. 
More advanced imaging-based features such as homogeneity, 
texture, or time changes of signals/images has been proposed 
